Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
US Manufacturing Index Rises To 43, Highest Since 2020
Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In...
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
